Clinical Trial Update: Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the safety and tolerability of RAD001 (everolimus) daily in Chinese patients with advanced pulmonary neuroendocrine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Neuroendocrine Tumors, Carcinoid Tumor | Phase 1, Phase 2 | Status: UNKNOWN